title: Regulation of cell survival by resveratrol involves inhibition of NF kappa B-regulated gene expression in prostate cancer cells.
abstract: BACKGROUND
  Polyphenols have been proposed as antitumoral agents. We have shown that resveratrol (RES) induced cell cycle arrest and promoted apoptosis in prostate cancer cells by inhibition of the PI3K pathway. The RES effects on NF kappaB activity in LNCaP cells (inducible NF kappaB), and PC-3 cells (constitutive NF kappaB) are reported.
  
  
  METHODS
  Cells were treated with 1-150 microM of RES during 36 hr. NF kappaB subcellular localization was analyzed by western blot and immunofluorescence. I kappaB alpha was evaluated by immunoprecipitation followed by Western blot. Specific DNA binding of NF kappaB was determined by EMSA assays and NF kappaB-mediated transcriptional activity by transient transfection with a luciferase gene reporter system.
  
  
  RESULTS
  RES induced a dose-dependent cytoplasmic retention of NF kappaB mediated by I kappaB alpha in PC-3 cells but not in LNCaP. RES-induced inhibition of NF kappaB specific binding to DNA was more significant in PC-3 cells. NF kappaB-mediated transcriptional activity induced by EGF and TNFalpha were inhibited by RES in both cell lines. LY294002 mimicked RES effects on NF kappaB activity.
  
  
  CONCLUSIONS
  Antiproliferative and apoptotic effects of RES on human prostate cancer cells may be mediated by the inhibition of NF kappaB activity. This mechanism seems to be associated to RES-induced PI3K inhibition. RES could have therapeutic potential for prostate cancer treatment.
authors.affiliation: Laboratorio de Andrología Celular y Molecular, PDFB, Universidad de Chile, Santiago, Chile.
authors.forename: Dixan A
authors.initials: DA
authors.lastname: Benitez
authors.forename: Marcela A
authors.initials: MA
authors.lastname: Hermoso
authors.forename: Eulalia
authors.initials: E
authors.lastname: Pozo-Guisado
authors.forename: Pedro M
authors.initials: PM
authors.lastname: Fernández-Salguero
authors.forename: Enrique A
authors.initials: EA
authors.lastname: Castellón
mesh_terms: D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D021122:Protein Subunits / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism; D000077185:Resveratrol; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D013267:Stilbenes / Q000494:pharmacology* / Q000627:therapeutic use; D013347:Subcellular Fractions / Q000187:drug effects / Q000378:metabolism; D051996:Transcription Factor RelA / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism
chemical_list: D016588:Anticarcinogenic Agents; D016328:NF-kappa B; D021122:Protein Subunits; D013267:Stilbenes; D051996:Transcription Factor RelA; D000077185:Resveratrol